Companion Diagnostics Market: as Foundation Medicine's seven simultaneous breast cancer companion diagnostic indications and 60% share of all US next-generation sequencing companion diagnostic approvals reveal a market where a single comprehensive genomic profiling platform increasingly decides which patients reach which targeted therapy, each new FDA approval broadens the indication list without requiring a new laboratory contract or instrument placement, so per-platform revenue compounds above the new drug approval rate, and the biopharmaceutical industry's growing preference for validated multi-indication platforms over bespoke single-gene tests concentrates future co-development spending at the companies that have already demonstrated the fastest regulatory conversion.

The global companion diagnostics market size was USD 7.50 Billion in 2025 and is expected to register a revenue CAGR of 12.8% during the forecast period. Market revenue growth is driven by factors such as Foundation Medicine's rapid succession of FDA companion diagnostic approvals across multiple cancer types, Roche's integrated diagnostics-pharmaceuticals revenue scale, and the structural shift in oncology drug development toward biomarker-defined patient selection that makes companion diagnostic testing a mandatory component of targeted therapy commercialisation. The first driving factor is the self-reinforcing flywheel effect of Foundation Medicine's multi-indication approval accumulation. Foundation Medicine holds 60% of all US companion diagnostic approvals for next-generation sequencing testing, creating a regulatory and clinical trial design expertise base that makes the company the lower-risk default partner for biopharmaceutical companies developing new targeted oncology therapies, so each additional approval further strengthens the platform's position as the preferred co-development partner. The second driving factor is Roche's integrated diagnostics-pharmaceuticals structural advantage. Roche reported companion diagnostic and predictive biomarker revenue exceeding CHF 2.40 Billion in October 2024, growing 12% year over year, driven by VENTANA PD-L1 SP142, FoundationOne CDx, and cobas EGFR and KRAS mutation assays deployed across more than 5,800 pathology and molecular laboratories globally, with the Genentech pharmaceutical arm providing internal drug development pipeline alignment that external diagnostic-only companies cannot replicate. The third driving factor is the projected companion biomarker requirement for approximately 50% of new cancer drugs in development. These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way each FDA companion diagnostic approval adds a new billable indication to an already-installed comprehensive genomic profiling platform, which compounds per-platform revenue without requiring a new laboratory contract, a new instrument placement, or a new clinical trial partnership. Once a hospital or reference laboratory has the FoundationOne CDx or FoundationOne Liquid CDx platform running on its standard oncology diagnostic menu, each additional companion diagnostic indication approved for that platform generates incremental per-test billing without any incremental laboratory capital investment or menu change process, so the revenue per installed platform compounds in value as the indication list broadens around it. As a result, demand and revenue share are concentrating around the comprehensive genomic profiling platforms that hold the broadest validated companion diagnostic indication lists, and the forecast tilts toward these multi-indication incumbents rather than the single-gene PCR assay developers whose revenue ceiling is bounded by a single approved drug indication. For instance, in October 2024, Foundation Medicine received FDA approval for FoundationOne Liquid CDx as a companion diagnostic for Itovebi in combination with palbociclib and fulvestrant, identifying hormone receptor-positive, HER2-negative breast cancer patients with a PIK3CA mutation through a routine blood draw, adding one of more than seven simultaneous breast cancer companion diagnostic indications the platform now carries and confirming that the per-platform revenue compounding mechanism is operating in real-time commercial approval cycles. These are some of the key factors driving revenue growth of the market.

The clearest driver of demand is Foundation Medicine's systematic accumulation of companion diagnostic indications across its FoundationOne CDx tissue-based and FoundationOne Liquid CDx blood-based platforms, which has created a regulatory and clinical portfolio depth that biopharmaceutical companies treat as the most reliable path to companion diagnostic co-development. The platform accumulation flywheel works because each prior approval generates regulatory expertise and clinical trial design precedent that makes the next companion diagnostic submission faster and lower-risk for both Foundation Medicine and its biopharmaceutical partner, so the marginal cost of each additional indication declines as the approval track record broadens. The recent record shows the pace. Foundation Medicine received FDA approval in October 2024 for FoundationOne Liquid CDx as a companion diagnostic for Itovebi in combination with palbociclib and fulvestrant for PIK3CA-mutated breast cancer, bringing the platform to seven companion diagnostic indications for breast cancer. In September 2024, the company received FDA approval for FoundationOne CDx and FoundationOne Liquid CDx as companion diagnostics for Lynparza in combination with abiraterone for BRCA-mutated metastatic castration-resistant prostate cancer, bringing it to seven prostate cancer indications, and in November 2024 it received FDA approval for FoundationOne Liquid CDx as the first companion diagnostic for TEPMETKO identifying MET exon 14 skipping alterations in non-small cell lung cancer. The effect on the market is a structural per-platform revenue uplift at every hospital and reference laboratory running either FoundationOne platform, creating a growth rate above the underlying new cancer drug approval rate as the indication list compounds around the same installed platform. These are some of the key factors driving revenue growth of the market.

The second driver is Roche's integrated diagnostics-pharmaceuticals corporate structure, which allows the company to design companion diagnostic development programmes in parallel with Genentech internal drug development from day one of a clinical programme, eliminating the external partnership coordination timeline that pure-play diagnostic companies managing external pharmaceutical partnerships face. This integration advantage compounds because Roche can allocate internal capital to companion diagnostic development without external partner negotiation, can align clinical trial design to optimise both therapeutic and diagnostic endpoints simultaneously, and can deploy the resulting companion diagnostic across its 5,800-laboratory global installed base immediately upon FDA approval. Roche reported companion diagnostic and predictive biomarker revenue exceeding CHF 2.40 Billion in October 2024, representing 12% year-over-year growth, driven by VENTANA PD-L1 SP142 immunohistochemistry testing supporting atezolizumab treatment selection, FoundationOne CDx comprehensive genomic profiling, and cobas EGFR and KRAS mutation assays supporting osimertinib and adagrasib treatment selection. Approximately 50% of new cancer drugs in development are projected to have a companion biomarker, a structural trend that favours Roche's integrated model over diagnostic-only or pharmaceutical-only competitors managing external partnerships independently. The effect on the market is a durable integrated competitive moat that becomes stronger as the drug development pipeline biomarker requirement rate increases, making Roche's dual position as the parent of both Foundation Medicine and Genentech a compounding structural advantage over the forecast period. These are some of the key factors driving revenue growth of the market.

"Foundation Medicine carrying 60% of all US NGS companion diagnostic approvals and more than seven simultaneous breast cancer indications is the clearest example of why whoever solves the multi-indication comprehensive genomic profiling regulatory pathway, not whoever has the most sensitive single-gene assay, captures the durable revenue in this market."

Clarivant Analyst Intelligence, 2025

The third driver is the structural transformation of oncology drug development toward biomarker-defined patient selection, which embeds companion diagnostic testing as a mandatory regulatory requirement for targeted therapy market access rather than an optional clinical practice enhancement. Structural embedding works as a demand driver because the companion diagnostic requirement is established during clinical trial design rather than at the point of product launch, so the demand for companion diagnostic testing is locked in several years before the therapeutic reaches commercial approval, creating a forward-revenue pipeline that is visible, quantifiable, and independent of post-launch adoption behaviour. Industry analysis documents that approximately 50% of new cancer drugs currently in development are projected to have a companion biomarker requirement, a structural shift from less than 20% a decade ago, and FDA's companion diagnostic approval framework has matured to handle parallel therapeutic-diagnostic co-approvals efficiently across all oncology drug modalities. The effect on the market is a growing pipeline of companion diagnostic approvals following each new targeted therapy FDA approval, creating a structural growth floor for companion diagnostic test volume that does not require any additional market development effort from the diagnostic companies and instead grows proportionally with the rate of targeted oncology drug approvals. These are some of the key factors driving revenue growth of the market.

However, the companion diagnostics market faces adoption constraints from the substantial market concentration around Foundation Medicine's comprehensive genomic profiling platform and the structural coupling of companion diagnostic approval to therapeutic drug approval timelines. Because Foundation Medicine holds 60% of all US NGS companion diagnostic approvals, biopharmaceutical companies developing targeted therapies face dependency risk from concentrating co-development relationships at a single platform provider, and this market concentration limits the competitive pricing pressure that might otherwise accelerate test volume growth by reducing per-test costs at hospital and reference laboratory accounts managing constrained diagnostic testing budgets. Companion diagnostic approval timeline coupling is a second constraint, since diagnostic test developers cannot independently accelerate their own market entry, must align development resources to specific biopharmaceutical partner clinical programmes that carry their own enrolment, efficacy, and regulatory risk, and must navigate FDA co-review processes that synchronise diagnostic and therapeutic approval timelines, creating revenue realisation timing uncertainty that is structurally outside the diagnostic company's control and makes forward revenue planning unusually dependent on external partner programme outcomes. Capital equipment spending caution is a third constraint, since QIAGEN's 2024 results showed larger-scale instrument sales remained challenging even as consumables and related revenue continued to drive growth, reflecting the broader healthcare capital equipment spending caution that has constrained new companion diagnostic platform instrument placement at hospital and reference laboratory accounts managing multi-year capital budget cycles, so new entrant platforms without an established instrument installed base face a slower commercialisation trajectory than incumbent platforms already present at high-volume oncology testing centres. These factors substantially limit companion diagnostics market growth over the forecast period.

Based on technology, the global companion diagnostics market is segmented into next-generation sequencing, PCR-based testing, in situ hybridization, and liquid biopsy and circulating tumor DNA testing. Next-generation sequencing holds the largest revenue share, because the FoundationOne CDx comprehensive genomic profiling platform assesses all classes of genomic alterations across 324 cancer-related genes and holds companion diagnostic indications for 17 on-label targeted therapies across multiple cancer types, which suits the oncology drug development trend toward multi-indication platform co-development that allows a single NGS test to serve as the companion diagnostic for multiple simultaneous therapeutic approvals. PCR-based testing and IHC/FISH remain established for single-gene mutation detection and protein expression scoring respectively, serving as the diagnostic backbone for older companion diagnostic approvals where tissue-based single-analyte testing was the regulatory standard, and they are more cost-accessible for individual targeted tests, but they cannot match the multi-indication breadth of the comprehensive genomic profiling platforms. Liquid biopsy and circulating tumor DNA testing is expected to register a rapid revenue growth rate in the global companion diagnostics market over the forecast period, driven by FoundationOne Liquid CDx's expanding companion diagnostic indication list across breast cancer, prostate cancer, and non-small cell lung cancer, with Foundation Medicine chief medical officer Mia Levy specifically noting that the blood draw accessibility advantage broadens patient eligibility relative to tissue biopsy procedures.

Based on indication, the global companion diagnostics market is segmented into non-small cell lung cancer, breast cancer, prostate cancer, and other solid tumors. Non-small cell lung cancer holds the largest revenue share, reflecting the disease's high mutation burden and the broad range of approved targeted therapies addressing EGFR mutations, ALK rearrangements, ROS1 fusions, and MET exon 14 skipping alterations, each requiring distinct companion diagnostic testing. Foundation Medicine's November 2024 FDA approval of FoundationOne Liquid CDx as the first companion diagnostic for TEPMETKO identifying MET exon 14 skipping alterations extends the company's NSCLC companion diagnostic breadth further. Breast cancer is expected to register a rapid revenue growth rate over the forecast period, driven by Foundation Medicine's seven simultaneous companion diagnostic indications for breast cancer and the October 2024 FDA approval of FoundationOne Liquid CDx as a companion diagnostic for the PIK3CA-mutated breast cancer therapy Itovebi, expanding liquid biopsy companion diagnostic testing into the endocrine-resistant breast cancer patient population.

Based on sample type, the global companion diagnostics market is segmented into tissue biopsy and blood-based liquid biopsy. Tissue biopsy holds the largest current revenue share through the established FoundationOne CDx tissue-based comprehensive genomic profiling platform and the broader installed base of immunohistochemistry and fluorescence in situ hybridization testing at pathology laboratories globally, because tissue-based testing remains the standard of care for initial oncology diagnosis and the most clinically validated sample type for companion diagnostic biomarker assessment across most approved targeted therapy indications. Blood-based liquid biopsy is expected to register the fastest revenue growth rate in the global companion diagnostics market over the forecast period, driven by FoundationOne Liquid CDx's expanding companion diagnostic indication breadth and the structural accessibility advantage of routine blood draws over tissue biopsy procedures for patients with tumours in locations not amenable to re-biopsy, with Guardant360 CDx representing the leading specialist liquid biopsy competitor to Foundation Medicine's platform.

Based on regional analysis, the companion diagnostics market in North America accounted for largest revenue share in 2025. The United States leads because Foundation Medicine, headquartered in Cambridge, Massachusetts, holds 60% of all US companion diagnostic approvals for next-generation sequencing testing, and FDA companion diagnostic approvals are the primary global regulatory benchmark that determines which platforms receive commercial deployment across the major oncology testing centres. Roche's FoundationOne CDx and FoundationOne Liquid CDx platforms generate the substantial majority of their companion diagnostic revenue from the US market, supported by Centers for Medicare and Medicaid Services coverage frameworks that provide reimbursement pathways for FDA-approved companion diagnostic testing tied to specific therapeutic indications. The concentration of Foundation Medicine's regulatory approval activity and laboratory network in the United States also means that new companion diagnostic indications are validated and commercially deployed in the US market first before international regulatory submission.

The market in Europe is expected to register a steady revenue growth rate over the forecast period. Germany, the United Kingdom, and France represent the three largest national companion diagnostics markets within Europe, reflecting the concentration of major pharmaceutical company oncology development operations and established national health system biomarker testing reimbursement frameworks. Roche generates substantial European companion diagnostic revenue through VENTANA tissue diagnostics and cobas molecular diagnostics platforms deployed across European pathology laboratory networks. The ongoing Iran-US sanctions and disruption to specialty molecular diagnostic reagent supply chains passing through Strait of Hormuz logistics corridors through 2026 have maintained reagent procurement costs above pre-2022 baseline levels for European companion diagnostic reagent manufacturers. The result is steady rather than rapid growth, shaped more by reimbursement framework harmonisation pace across EU member states than by underlying oncology drug development activity.

The market in Asia Pacific is expected to register a rapid revenue growth rate over the forecast period. Japan, China, and South Korea represent the three largest national companion diagnostics markets within the region, driven by expanding precision oncology drug development activity and growing national regulatory approval pathways. Japan's Pharmaceuticals and Medical Devices Agency has established an increasingly streamlined regulatory pathway for companion diagnostic approval that often follows closely behind FDA approval timelines, and Japan's status as an early-launch market for many Foundation Medicine platform indications leaves more room for companion diagnostic test volume growth than in North America or Western Europe where penetration at major oncology centres is already more advanced.

The market in Latin America is expected to register a moderate revenue growth rate over the forecast period. Brazil and Mexico represent the two largest national companion diagnostics markets within the region, reflecting expanding regional precision oncology testing infrastructure investment. The Iran-US sanctions and Strait of Hormuz freight disruption have maintained elevated import costs for companion diagnostic molecular testing reagents entering Brazilian and Mexican distribution networks through 2026, slowing adoption of new companion diagnostic platforms beyond the primary oncology reference laboratory centres in Sao Paulo, Mexico City, and Bogota.

The market in Middle East and Africa is expected to register a moderate revenue growth rate over the forecast period. Saudi Arabia and the United Arab Emirates represent the primary commercial markets within the GCC, reflecting government investment in expanding national precision oncology infrastructure under healthcare modernisation programmes. South Africa is the most established companion diagnostics market on the African continent, supporting both domestic precision oncology testing and regional referral patterns for advanced genomic profiling services, while the Gulf states are still building the oncology specialist physician capacity and companion diagnostic reimbursement frameworks that would drive consistent test ordering volumes.